BrainStorm Cell Therapeutics to Deliver Mid-Year Update on NurOwn Program

BrainStorm Cell Therapeutics Inc., a prominent developer in the field of adult stem cell therapeutics for neurodegenerative diseases, has announced a mid-year corporate update slated for Monday, July 8, at 8:00 a.m. Eastern Time. This announcement was made on July 1, 2024, in New York.

The update will be presented by BrainStorm's President and CEO, Chaim Lebovits, along with the newly appointed Chief Operating Officer and Executive Vice President, Hartoun Hartounian, PhD. Chief Development Officer, Bob Dagher, MD, will also be present to address questions during the Q&A session following the prepared remarks.

Investors and other participants are encouraged to submit their questions in advance of the call, no later than 10:00 a.m. Eastern Time on Friday, July 5, 2024, via the provided email address. The investment community can join the conference call by dialing specific toll-free or international numbers and using the participant access code provided. There is also an option to listen to the webcast live.

For those who cannot attend the live session, a replay of the conference call will be available until Monday, July 22, 2024. The replay can be accessed by dialing the provided toll-free or international numbers and using the replay passcode.

BrainStorm Cell Therapeutics Inc. is recognized for its innovative work in developing autologous adult stem cell therapeutics aimed at treating severe neurodegenerative conditions. The company holds exclusive worldwide rights for the clinical development and commercialization of the NurOwn® technology platform. This platform is designed to produce autologous MSC-NTF cells, which have been granted Orphan Drug designation by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) specifically for the treatment of amyotrophic lateral sclerosis (ALS).

BrainStorm has successfully completed a Phase 3 trial in ALS, identified as NCT03280056. This trial focused on the safety and efficacy of repeated administration of autologous MSC-NTF cells and was supported by grants from the California Institute for Regenerative Medicine, the ALS Association, and I AM ALS.

In addition, BrainStorm has conducted a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. This investigational new drug application represents a significant step forward in BrainStorm's mission to develop effective treatments for challenging neurodegenerative disorders.

This mid-year update will provide an opportunity for BrainStorm to share recent positive developments in the NurOwn® program with the investment community and other stakeholders. Through this open communication, the company aims to keep its investors well-informed about its progress and future plans in the realm of neurodegenerative disease therapeutics.